RMC No. 129-2022 updates the VAT-exempt medicines list under the CREATE Act, removing certain mental health medicines and requiring businesses to apply 12% VAT immediately.
Businesses in the pharmaceutical sector, healthcare providers, and distributors must take immediate note: certain medicines previously exempt from VAT under Republic Act No. 11534 (CREATE Act) are now removed from the VAT-exempt list. This change impacts sales invoicing, VAT reporting, and compliance obligations.
What Changed
RMC No. 129-2022, issued on September 20, 2022, publishes the September 1, 2022 letter from the Food and Drug Administration (FDA) Director General Samuel A. Zacate. The circular endorses updates to the official